Tech Company Financing Transactions
Xanthus Pharmaceuticals Funding Round
On 12/12/2003, Xanthus Pharmaceuticals secured $30.8 million in Series B investment from Oxford Bioscience Partners, CDIB Bioscience and HealthCare Ventures.
Transaction Overview
Company Name
Announced On
12/12/2003
Transaction Type
Venture Equity
Amount
$30,800,000
Round
Series B
Investors
Oxford Bioscience Partners (Lead Investor) (Mark Carthy)
Proceeds Purpose
This latest financing will be used to fund clinical trials of Xanthus' drugs in 2004.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
300 Technology Square 5th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Xanthus is a biopharmaceutical company focused on the discovery, development, acquisition and commercialization of small-molecule therapeutics for the treatment of cancer and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Richard Dean
Chief Financial Officer
Robert Boisjoli
Chief Medical Officer
Robert Capizzi
Chief Operating Officer
Michael Boss
Chief Scientific Officer
Alfred Ajami
Vice President
John Lister-James
VP - Regulatory Affairs
Kris Piper
Browse more venture capital transactions:
Prev: 12/10/2003: GlycoFi venture capital transaction
Next: 12/12/2003: NeoGuide Systems venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs